OBJECTIVE To analyze the research status， hotspot and development trend of tyrosine kinase inhibitors （TKIs） in the treatment of human epidermal growth factor receptor 2 （HER2） positive breast cancer. METHODS The literature related to TKIs in the treatment of HER2 positive breast cancer were searched from the Web of Science core collection database； the author， country/region， institution， subject field， journal and keywords was visualized by CiteSpace 6.1.R3 software. RESULTS A total of 732 pieces of literature were included， and the number of literature published showed an increasing trend year by year. The number of literature published in the United States was the largest （center degree 0.10）， and the number of literature published in China ranked second （center degree 0.05）. The most published and cited authors were Crown from St. Vincent’s University Hospital in Australia and Slamon from University of California， Los Angeles in the United States； the institution with the highest number of literature was the University of Texas MD Anderson Cancer Center， and the journal with the highest number of literature was the Journal of Clinical Oncology. The research mainly focused on five aspects： HER2 positive breast cancer treatment drugs， TKIs receptor， TKIs mechanism of action， HER2 positive breast cancer brain metastasis， and TKIs clinical trials. The main frontier areas and development trends were the combination of TKIs with other drugs or therapies to enhance targeting and reduce toxic side effects. CONCLUSIONS The study of TKIs in the treatment of HER2 positive breast cancer has attracted the attention of scholars at home and abroad. Chinese scholars and research teams need to strengthen cooperation and communication in the future， and cooperation with other countries should be strengthened in terms of the efficacy and safety of TKIs alone and combined with other drugs in the treatment of HER2 positive breast cancer.

Objective:To study the application value of health education based on self-efficacy theory in the management of patients with chronic obstructive pulmonary disease (COPD) outside the hospital.Methods:Using the convenient sampling method, a total of 66 COPD patients who were treated and discharged from the First Affiliated Hospital of Zhengzhou University from March to November 2018 were selected as the routine group, and 67 COPD patients who were treated and discharged from December 2018 to August 2019 were selected as the study group. The routine group adopted routine follow-up nursing, while the study group adopted health education based on self-efficacy theory on the basis of routine follow-up nursing. The rehabilitation compliance score and self-efficacy score of the two groups before the intervention, after the intervention and 6 months after the intervention were compared. The readmission rate from the beginning of the intervention to 6 months after the intervention were compared between the two groups.Results:After the intervention, the rehabilitation compliance score of the study group was (39.94±4.91) , which was higher than (33.29±4.60) of the routine group. At 6 months after intervention, the rehabilitation compliance score of the study group was (38.87±4.76) , which was higher than (31.75±4.10) of the conventional group. Repeated measurement analysis of variance showed that there was an interaction between the two groups in rehabilitation compliance score ( Ftime=84.532, Fgroups=10.241, Finteraction=9.785; P<0.05) . After intervention, the self-efficacy score of the study group was (141.36±20.76) , higher than (118.26±15.47) of the control group. On 6 months after the intervention, the self-efficacy score of the study group was (139.21±16.95) , which was higher than (108.51±15.01) of the routine group. Repeated measurement analysis of variance showed that there was an interaction between the two groups in self-efficacy scores ( Ftime=87.541, Fgroups=12.254, Finteraction=13.697; P<0.05) . At 6 months after intervention, the readmission rate of the study group was 16.42%, which was lower than 33.33% of the routine group, and the difference was statistically significant ( χ2=5.099, P=0.024) . Conclusions:The application of health education based on self-efficacy theory in the management of COPD patients outside the hospital can improve rehabilitation compliance and self-efficacy of patients and reduce the frequency of readmissions.

The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. Twelve patients with advanced gastric cancer were recruited to the study. The dose of S-1 for each patient was determined according to his/her body surface area (BSA). The dose for single administration was 60 mg every subject. The dose for multiple administration for one subject was as follows: 100 mg x d(-1) or 120 mg x d(-1), 28-days consecutive oral administration. The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220.0 +/- 68.2), (374.9 +/- 103.0), (110.5 +/- 100.8) and (831.1 +/- 199.9) ng x mL(-1) for Cmax; (11.8 +/- 3.8), (4.4 +/- 3.3), (7.8 +/- 5.1), (3.1 +/- 0.9) and (8.8 +/- 4.1) h for t1/2, respectively. After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively. The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1. The results exhibited that tegafur had some drug accumulation observed, and gimeracil, potassium oxonate, 5-fluorouracil and uracil had no drug accumulation observed.

A simple method for the isolation and purification of ginkgolide A, B and bilobalide(ginkgo terpene trialctone) was developed. A commercially available extract of leaves of Ginkgo biloba L.containing ＞6％ ginkgo terpene trilactone was used as the raw material. After partition in EtOAc, the en-riched extract was separated to give individual terpenes by preparative liquid chromatography. GinkgolideA, B and bilobalide could be isolated with high purity by recrystallizing in MeOH-H2O.